Connection

Jeffrey Jones to Humans

This is a "connection" page, showing publications Jeffrey Jones has written about Humans.
Connection Strength

0.439
  1. Connective Tissue Disorders and Cardiovascular Complications: The Indomitable Role of Transforming Growth Factor-? Signaling. Adv Exp Med Biol. 2021; 1348:161-184.
    View in: PubMed
    Score: 0.028
  2. Pathophysiology and Pathogenesis of Marfan Syndrome. Adv Exp Med Biol. 2021; 1348:185-206.
    View in: PubMed
    Score: 0.028
  3. Elevated Wall Tension Leads to Reduced miR-133a in the Thoracic Aorta by Exosome Release. J Am Heart Assoc. 2019 01 08; 8(1):e010332.
    View in: PubMed
    Score: 0.025
  4. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 01; 19(1):65-75.
    View in: PubMed
    Score: 0.023
  5. A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018 01; 180(2):259-266.
    View in: PubMed
    Score: 0.023
  6. Oxidative stress in bicuspid aortic valve-related aortopathy: Hand-me-downs and yoga pants. J Thorac Cardiovasc Surg. 2017 11; 154(5):1764-1765.
    View in: PubMed
    Score: 0.022
  7. Regulation of membrane type-1 matrix metalloproteinase activity and intracellular localization in clinical thoracic aortic aneurysms. J Thorac Cardiovasc Surg. 2017 03; 153(3):537-546.
    View in: PubMed
    Score: 0.021
  8. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability. J Vasc Res. 2016; 53(1-2):1-16.
    View in: PubMed
    Score: 0.021
  9. Editorial Commentary: Understanding Marfan syndrome, or "how not to invent the light bulb". Trends Cardiovasc Med. 2016 07; 26(5):429-32.
    View in: PubMed
    Score: 0.020
  10. Invited commentary. Ann Thorac Surg. 2015 Jan; 99(1):71.
    View in: PubMed
    Score: 0.019
  11. Connective tissue disorders and cardiovascular complications: the indomitable role of transforming growth factor-beta signaling. Adv Exp Med Biol. 2014; 802:107-27.
    View in: PubMed
    Score: 0.017
  12. Plasma biomarkers for distinguishing etiologic subtypes of thoracic aortic aneurysm disease. J Thorac Cardiovasc Surg. 2013 May; 145(5):1326-33.
    View in: PubMed
    Score: 0.016
  13. Aortic dilatation with bicuspid aortic valves: cusp fusion correlates to matrix metalloproteinases and inhibitors. Ann Thorac Surg. 2012 Feb; 93(2):457-63.
    View in: PubMed
    Score: 0.015
  14. Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction. Circ Cardiovasc Genet. 2011 Dec; 4(6):605-13.
    View in: PubMed
    Score: 0.015
  15. The pathogenesis of aortopathy in Marfan syndrome and related diseases. Curr Cardiol Rep. 2010 Mar; 12(2):99-107.
    View in: PubMed
    Score: 0.013
  16. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res. 2009; 46(2):119-37.
    View in: PubMed
    Score: 0.012
  17. Differential protein kinase C isoform abundance in ascending aortic aneurysms from patients with bicuspid versus tricuspid aortic valves. Circulation. 2007 Sep 11; 116(11 Suppl):I144-9.
    View in: PubMed
    Score: 0.011
  18. Identification of a novel phosphatidic acid binding domain in protein phosphatase-1. Biochemistry. 2005 Oct 11; 44(40):13235-45.
    View in: PubMed
    Score: 0.010
  19. Tight binding inhibition of protein phosphatase-1 by phosphatidic acid. Specificity of inhibition by the phospholipid. J Biol Chem. 2002 May 03; 277(18):15530-8.
    View in: PubMed
    Score: 0.008
  20. Focusing Heart Failure Research on Myocardial Fibrosis to Prioritize Translation. J Card Fail. 2020 Oct; 26(10):876-884.
    View in: PubMed
    Score: 0.007
  21. Relation of Lymphangiogenic Factor Vascular Endothelial Growth Factor-D to Elevated Pulmonary Artery Wedge Pressure. Am J Cardiol. 2019 09 01; 124(5):756-762.
    View in: PubMed
    Score: 0.006
  22. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017 Aug 01; 127(8):3052-3064.
    View in: PubMed
    Score: 0.006
  23. A reproducible swine model of proximal descending thoracic aortic aneurysm created with intra-adventitial application of elastase. J Vasc Surg. 2018 01; 67(1):300-308.e2.
    View in: PubMed
    Score: 0.006
  24. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. Am J Hematol. 2015 Nov; 90(11):967-9.
    View in: PubMed
    Score: 0.005
  25. HDACs Regulate miR-133a Expression in Pressure Overload-Induced Cardiac Fibrosis. Circ Heart Fail. 2015 Nov; 8(6):1094-104.
    View in: PubMed
    Score: 0.005
  26. Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment. Neoplasia. 2015 May; 17(5):434-48.
    View in: PubMed
    Score: 0.005
  27. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr; 1(1):80-7.
    View in: PubMed
    Score: 0.005
  28. Pulmonary arteriovenous malformations after the superior cavopulmonary shunt: mechanisms and clinical implications. Expert Rev Cardiovasc Ther. 2014 Jun; 12(6):703-13.
    View in: PubMed
    Score: 0.004
  29. Pathophysiology of thoracic aortic aneurysm (TAA): is it not one uniform aorta? Role of embryologic origin. Prog Cardiovasc Dis. 2013 Jul-Aug; 56(1):68-73.
    View in: PubMed
    Score: 0.004
  30. Differential membrane type 1 matrix metalloproteinase substrate processing with ischemia-reperfusion: relationship to interstitial microRNA dynamics and myocardial function. J Thorac Cardiovasc Surg. 2013 Jan; 145(1):267-275, 277.e1-4; discussion 275-7.
    View in: PubMed
    Score: 0.004
  31. Gene targeting in ischemic heart disease and failure: translational and clinical studies. Biochem Pharmacol. 2013 Jan 01; 85(1):1-11.
    View in: PubMed
    Score: 0.004
  32. Prophylactic surgery prior to extended-duration space flight: is the benefit worth the risk? Can J Surg. 2012 Apr; 55(2):125-31.
    View in: PubMed
    Score: 0.004
  33. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.004
  34. Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch. J Card Surg. 2012 Jan; 27(1):81-90.
    View in: PubMed
    Score: 0.004
  35. Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease. Br J Haematol. 2010 Mar; 148(5):754-9.
    View in: PubMed
    Score: 0.003
  36. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol. 2009 Dec 10; 27(35):6012-8.
    View in: PubMed
    Score: 0.003
  37. Regional heterogeneity within the aorta: relevance to aneurysm disease. J Thorac Cardiovasc Surg. 2008 Nov; 136(5):1123-30.
    View in: PubMed
    Score: 0.003
  38. Confluence induced threonine41/serine45 phospho-beta-catenin dephosphorylation via ceramide-mediated activation of PP1cgamma. Biochim Biophys Acta. 2007 Dec; 1771(12):1418-28.
    View in: PubMed
    Score: 0.003
  39. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg. 2007 Apr; 133(4):1028-36.
    View in: PubMed
    Score: 0.003
  40. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation. 2006 Jul 04; 114(1 Suppl):I365-70.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.